Japan· JP-3999044F1024
エボカルセト
A evocalcet product containing エボカルセト, registered in Japan by 協和キリン, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- エボカルセト
- Manufacturer
- 協和キリン
- Country
- Japan (JP)
- ATC code
- H05BX06
- ATC class
- Evocalcet
- Defined daily dose
- 2.5 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under H05BX06
Evocalcet, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b32a0342-d4b9-4276-9a87-7172e7ade560 GET /v1/drugs/b32a0342-d4b9-4276-9a87-7172e7ade560?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3999044F1024",
"category": "内用薬",
"price_yen": 271.9,
"generic_name": "エボカルセト",
"product_name_jp": null,
"therapeutic_class": "3999",
"transitional_expiry": null
}See everything about evocalcet.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.